ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's most innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 13, 2019 | Series A | $150M | 1 | UBS Oncology Impact Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
UBS Oncology Impact Fund | Yes | Series A |